Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that the chairman of its scientific advisory board, Dr Howard Weiner, will present positive data on intranasal anti-CD3 monoclonal antibody (mAb) in models of Alzheimer’s and Parkinson’s disease at an upcoming conference.
He will deliver the update at AD/PD, the annual international conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders, which is being held in Lisbon, Portugal from March 5 to 9.
The data is from the company’s research and development of its lead drug candidate intranasal foralumab, an anti-CD3 mAb.
“Our research has demonstrated that intranasal rodent anti-CD3 mAb and intranasal fully human anti-CD3 mAb (foralumab) will decrease microglia activation in rodents and humans, respectively,” Dr Weiner said in a statement.
“Nasal anti-CD3 has also shown to reduce hemorrhage and edema that occurs with ARIA.”
Tiziana's acting CEO, Gabriele Cerrone, added that, with its focus on effective Alzheimer’s disease treatments, it has the potential to be a novel, first-in-class neuroinflammatory modulator.
“Our intranasal approach has large potential as it does not target beta-amyloid or other proteins, but focuses on the neuroinflammatory process itself, which may be complementary or synergistic with existing FDA-approved treatments,” Cerrone said.
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy.